Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, UCSF Ink Cell Line Collaboration

NEW YORK (GenomeWeb News) – Sigma-Aldrich announced today that it has entered into a five-year deal with the University of California, San Francisco, to develop optimal cell lines for the production of monoclonal antibodies.
UCSF researchers will use the cell lines conduct the research into antibodies for a variety of cancer targets, autoimmune diseases, stem cell characteristics, and commonly neglected disease targets. The university will have free access to antibodies resulting from the partnership for its ongoing immunology and disease research, Sigma-Aldrich said.
Further terms of the alliance were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.